Form 4 for RXRX RECURSION PHARMACEUTICALS, INC.
Accepted 2022-06-16 00:00:00 ET · period of report 2022-06-14 · accession 0001209191-22-037629 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-06-16 | 2022-06-14 | RXRX | CHAVEZ R. MARTIN | Dir | A - Grant | $0.00 | +18.1K | 29.3K | +163% | $0 |
| D | 2022-06-16 | 2022-06-14 | RXRX | CHAVEZ R. MARTIN | Dir | A - Grant | $0.00 | +36.3K | 36.3K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2022-06-14 | A | A | 18,145 | $0.00 | 29,252 | D | — | — | (F1) Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 14, 2023 or the day prior to the Issuer's 2023 annual meeting of stockholders. |
| 2 | Derivative | Stock Option (right to buy) | 2022-06-14 | A | A | 36,290 | $0.00 | 36,290 | D | $6.20 · 2023-06-14 to 2032-06-14 | 36,290 Class A Common Stock |